the effects of atorvastatin consumption on biochemical variables in patients with type 2 diabetes mellitus and pre-diabetes

Background and aims: atorvastatin may alter glycemic traits and lipid profiles. this study aimed to evaluate the effects of atorvastatin on biochemical variables in patients with type 2 diabetes and pre-diabetes (borderline diabetes). materials and methods: this study included 80 individuals divided into five groups. patients with type 2 diabetes mellitus and pre-diabetes used atorvastatin 20 mg/day for three months. after three months, variables such as serum fasting blood glucose (fbs), cholesterol, triglyceride, low-density lipoprotein-cholesterol (ldl-c), high-density lipoprotein-cholesterol (hdl-c), and glycosylated hemoglobin (hba1c) levels were measured to assess the status of diabetes and pre-diabetes condition. linear regression was applied to determine the association between atorvastatin uses and alters of biochemical variables levels. results: the serum fbs and hba1c levels in patients with diabetes and pre-diabetes who use atorvastatin were significantly lower than in patients with diabetes and pre-diabetes who did not use atorvastatin (p=0.001). serum cholesterol and ldl-c levels decreased in diabetic and pre-diabetic patients who used atorvastatin in comparison with diabetic and pre-diabetic patients who did not use atorvastatin (p=0.001). in patients with pre-diabetes, the use of atorvastatin slightly increased serum hdl-c levels. however, in patients with diabetes, the use of atorvastatin slightly decreased serum hdl-c level (p= 0.001). diabetic and pre-diabetic patients who use atorvastatin significantly decreased serum triglyceride levels (p=0.016), while in diabetic and pre-diabetic patients, using atorvastatin slightly increased the serum insulin level (p= 0.003). conclusions: atorvastatin using alters fat and sugar indices in diabetic and pre-diabetic patients.